Aakaar Medical Technologies Limited, founded in 2013, is a medical aesthetics company supplying a broad range of cosmetic products and devices to dermatologists, plastic surgeons, and aesthetic physicians across India. The company operates on a business-to-business (B2B) model, offering both its own brands and imported products from countries such as Korea, Spain, Italy, and Austria. With a diverse product portfolio and a growing customer base, Aakaar has demonstrated strong financial growth in recent years. The company aims to raise ₹27.00 crore through Aakaar Medical Technologies IPO, which opens for subscription from June 20 to June 24, 2025.
₹00
₹72
₹75.00
Expert Opinions
Market sentiment for Aakaar Medical Technologies IPO is cautiously optimistic, reflecting the company’s established presence in the medical aesthetics sector and its ability to cater to a growing demand among dermatologists and aesthetic professionals. The company’s strengths include a diverse product portfolio, strong B2B relationships, and access to both domestic and international brands, which have contributed to robust financial growth. However, risks and challenges remain, such as intense competition, regulatory uncertainties, and reliance on imported products.
Aakaar Medical Technologies IPO highlights strong financial metrics for FY 2025, with a Return on Equity (ROE) of 33.81%, Return on Capital Employed (ROCE) of 21.02%, and a Net Asset Value (NAV) of ₹22.26. From a long-term investment perspective, Aakaar’s consistent growth and sectoral tailwinds present promising prospects, but investors should remain mindful of potential market and operational risks before committing capital.
Investor Considerations
Investors evaluating Aakaar Medical Technologies IPO should note the company’s steady performance, with FY 2025 revenue at ₹61.76 crore and a PAT margin of 9.81%, reflecting sound fundamentals and operational efficiency. The medical aesthetics sector in India is experiencing robust growth, driven by rising demand for cosmetic procedures and technological advancements, which bodes well for Aakaar’s future prospects.
The Aakaar Medical Technologies IPO valuation shows a Price to Book Value of 5.23, a manageable debt/equity ratio of 0.98, and healthy profitability metrics, indicating a balanced financial position. Growth prospects are supported by a diverse product portfolio and expanding market reach. However, risk factors include sector competition, regulatory changes, and reliance on imported products. For investment horizon, short-term gains may be influenced by listing volatility, while long-term investors could benefit from sectoral growth and the company’s improving fundamentals.
| Date | GMP | Trend |
|---|---|---|
| 26 Jun 2025 11.18 | ₹00 | --- |
| 25 Jun 2025 14.17 | ₹00 | --- |
| 24 Jun 2025 11.06 | ₹00 | --- |
| 23 Jun 2025 10.38 | ₹00 | --- |
| 21 Jun 2025 10.52 | ₹00 | --- |
| 20 Jun 2025 10.38 | ₹00 | --- |
| 19 Jun 2025 11.48 | ₹00 | --- |
| 18 Jun 2025 10.37 | ₹00 | --- |
| 17 Jun 2025 18.17 | ₹00 | --- |
FAQs
The Grey Market Premium showed limited accuracy in predicting Aakaar Medical Technologies IPO’s listing performance. With a final GMP of ₹0, it indicated a flat listing around the issue price of ₹72. However, the stock listed slightly higher at ₹75, delivering a modest gain of 4.17%. This resulted in a prediction error of 4.17%, where the GMP failed to anticipate the positive listing direction, showing weak reliability in this case.
Aakaar Medical Technologies IPO Current GMP is ₹00.
Aakaar Medical Technologies IPO Expected Returns is 0.00%.
Aakaar Medical Technologies IPO estimated listing price is ₹72.